• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

住院后发生的药物不良反应导致的患者死亡率:一项荟萃分析。

Mortality among patients due to adverse drug reactions that occur following hospitalisation: a meta-analysis.

机构信息

Department of Pharmacology, GMERS Medical College, Gotri, Vadodara, Gujarat, 390021, India.

出版信息

Eur J Clin Pharmacol. 2019 Sep;75(9):1293-1307. doi: 10.1007/s00228-019-02702-4. Epub 2019 Jun 11.

DOI:10.1007/s00228-019-02702-4
PMID:31183532
Abstract

PURPOSE

To estimate the prevalence of mortality among patients that develop adverse drug reactions during hospitalisation (ADR), to examine heterogeneity through subgroup analysis and to identify system-organ class (SOC) and their causative drugs.

METHODS

Two investigators searched PubMed, Google Scholar and related bibliography for studies reporting ADR-related mortality data. The primary outcome was to compute overall prevalence of fatal ADR (95% CI) using double arcsine method. We explored the heterogeneity (I) in its estimation based on study design, study population and data collection methods. The secondary outcomes were the pattern of fatal reactions and their causative drugs. PROSPERO register number-CRD42018090331.

RESULTS

Out of 349 full text assessed, 48 studies satisfying the selection criteria were included. The fatal ADR prevalence was 0.11% (95% CI 0.06-0.18%; I = 93%). The fatal ADR prevalence ranged from 0.03% (I = 0%) in all ages to 0.27% (I = 90%) in elderly population studies. Elderly studies varied for all study characteristics. Among study wards, a higher trend of prevalence was observed in 'internal medicine and ICU' (0.46%, I = 51%) and 'neonatal/paediatric ward and ICU' (0.34%, I = 58%) studies. The commonly involved SOC were 'gastrointestinal disorders' (28.79%), 'blood and lymphatic system disorders' (19.69%) and 'renal and urinary disorders' (13.64%). Most commonly observed causative drug-fatal ADR pairs were antithrombotics and nonsteroidal anti-inflammatory drugs induced gastrointestinal bleeding, and antineoplastic agents induced cytopenia.

CONCLUSION

ADR is an important cause of mortality. Age groups and study wards have important influence on prevalence of fatal ADR and its heterogeneity across studies. Few class drugs contribute to sizable proportion of ADR-related mortality.

摘要

目的

评估住院期间发生药物不良反应(ADR)的患者的死亡率,通过亚组分析评估异质性,并确定系统器官类别(SOC)及其致病药物。

方法

两名调查员搜索了 PubMed、Google Scholar 和相关文献,以查找报告 ADR 相关死亡率数据的研究。主要结局是使用双反正弦法计算致命 ADR 的总体患病率(95%CI)。我们根据研究设计、研究人群和数据收集方法探讨了其估计的异质性(I)。次要结局是致命反应的模式及其致病药物。PROSPERO 注册号-CRD42018090331。

结果

在评估的 349 篇全文中,有 48 篇符合选择标准的研究被纳入。致命 ADR 的患病率为 0.11%(95%CI 0.06-0.18%;I=93%)。致命 ADR 的患病率从所有年龄段的 0.03%(I=0%)到老年人群研究中的 0.27%(I=90%)不等。老年人群的研究在所有研究特征上均存在差异。在研究病房中,“内科和 ICU”(0.46%,I=51%)和“新生儿/儿科病房和 ICU”(0.34%,I=58%)的研究中观察到更高的患病率趋势。常见的 SOC 包括“胃肠道疾病”(28.79%)、“血液和淋巴系统疾病”(19.69%)和“肾脏和泌尿系统疾病”(13.64%)。最常见的观察到的致病药物-致命 ADR 对是抗血栓药物和非甾体抗炎药引起的胃肠道出血,以及抗肿瘤药物引起的细胞减少症。

结论

ADR 是导致死亡的一个重要原因。年龄组和研究病房对致命 ADR 的患病率及其在研究之间的异质性有重要影响。少数类别药物对与 ADR 相关的死亡率有相当大的贡献。

相似文献

1
Mortality among patients due to adverse drug reactions that occur following hospitalisation: a meta-analysis.住院后发生的药物不良反应导致的患者死亡率:一项荟萃分析。
Eur J Clin Pharmacol. 2019 Sep;75(9):1293-1307. doi: 10.1007/s00228-019-02702-4. Epub 2019 Jun 11.
2
Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis.因导致住院的药物不良反应而死亡的患者情况:一项荟萃分析。
Eur J Clin Pharmacol. 2018 Jun;74(6):819-832. doi: 10.1007/s00228-018-2441-5. Epub 2018 Mar 19.
3
Hospitalizations due to preventable adverse reactions-a systematic review.因可预防的不良反应导致的住院治疗——一项系统综述。
Eur J Clin Pharmacol. 2017 Apr;73(4):385-398. doi: 10.1007/s00228-016-2170-6. Epub 2016 Dec 2.
4
Drug-related deaths among inpatients: a meta-analysis.住院患者与药物相关的死亡:一项荟萃分析。
Eur J Clin Pharmacol. 2022 Feb;78(2):267-278. doi: 10.1007/s00228-021-03214-w. Epub 2021 Oct 18.
5
Impact of suspected adverse drug reactions on mortality and length of hospital stay in the hospitalised patients: a meta-analysis.疑似药物不良反应对住院患者死亡率和住院时间的影响:一项荟萃分析。
Eur J Clin Pharmacol. 2023 Jan;79(1):99-116. doi: 10.1007/s00228-022-03419-7. Epub 2022 Nov 18.
6
Incidence of Adverse Drug Reactions in Indian Hospitals: A Systematic Review of Prospective Studies.印度医院药物不良反应的发生率:前瞻性研究的系统评价
Curr Drug Saf. 2016;11(2):128-36. doi: 10.2174/1574886310666150921104523.
7
Detection of adverse drug reactions using hospital databases-a nationwide study in Portugal.利用医院数据库检测药物不良反应——葡萄牙全国性研究。
Pharmacoepidemiol Drug Saf. 2013 Aug;22(8):907-13. doi: 10.1002/pds.3468. Epub 2013 Jun 13.
8
Adverse-Drug-Reaction-Related Hospitalisations in Developed and Developing Countries: A Review of Prevalence and Contributing Factors.发达国家和发展中国家与药物不良反应相关的住院情况:患病率及影响因素综述
Drug Saf. 2016 Sep;39(9):847-57. doi: 10.1007/s40264-016-0444-7.
9
Adverse drug reactions leading to urgent hospital admission in an elderly population: prevalence and main features.导致老年人群紧急住院的药物不良反应:患病率及主要特征
Eur J Clin Pharmacol. 2016 Feb;72(2):219-26. doi: 10.1007/s00228-015-1974-0. Epub 2015 Nov 7.
10
Prevalence of fatal adverse drug reactions in hospitalized patients.住院患者中致命药物不良反应的发生率。
Int J Clin Pharmacol Ther. 2009 Oct;47(10):596-602. doi: 10.5414/cpp47596.

引用本文的文献

1
An automation framework for clinical codelist development validated with UK data from patients with multiple long-term conditions.一个用于临床代码列表开发的自动化框架,已通过来自患有多种长期疾病患者的英国数据进行验证。
BMC Med Res Methodol. 2025 May 24;25(1):138. doi: 10.1186/s12874-025-02541-1.
2
Chemotherapy-related adverse drug reaction and associated factors among adult cancer patient attending Jimma medical center oncology unit, Southwest Ethiopia.埃塞俄比亚西南部吉马医疗中心肿瘤科成年癌症患者中与化疗相关的药物不良反应及相关因素
PLoS One. 2025 May 16;20(5):e0321785. doi: 10.1371/journal.pone.0321785. eCollection 2025.
3

本文引用的文献

1
Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis.因导致住院的药物不良反应而死亡的患者情况:一项荟萃分析。
Eur J Clin Pharmacol. 2018 Jun;74(6):819-832. doi: 10.1007/s00228-018-2441-5. Epub 2018 Mar 19.
2
Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data.化疗引起的中性粒细胞减少症(CIN)和发热性中性粒细胞减少症(FN)对癌症治疗结果的影响:对已确立和最近出现的临床数据的概述。
Crit Rev Oncol Hematol. 2017 Dec;120:163-179. doi: 10.1016/j.critrevonc.2017.11.005. Epub 2017 Nov 11.
3
The Clinical Pharmacist-Led Medication Review Service at the Surgical Department: A Feasibility Study.
外科临床药师主导的药物审查服务:一项可行性研究。
Scand J Caring Sci. 2025 Jun;39(2):e70030. doi: 10.1111/scs.70030.
4
Knowledge, attitude, and practice among community pharmacists toward adverse drug reaction reporting and pharmacovigilance: A nationwide survey.社区药剂师对药品不良反应报告和药物警戒的知识、态度及实践:一项全国性调查。
Explor Res Clin Soc Pharm. 2025 Feb 18;18:100578. doi: 10.1016/j.rcsop.2025.100578. eCollection 2025 Jun.
5
An innovative method to strengthen evidence for potential drug safety signals using Electronic Health Records.利用电子健康记录加强潜在药物安全信号证据的创新方法。
J Med Syst. 2024 May 16;48(1):51. doi: 10.1007/s10916-024-02070-2.
6
Council of Europe Resolution on the Implementation of Pharmaceutical Care-A Step Forward in Enhancing the Appropriate Use of Medicines and Patient-Centred Care.欧洲委员会关于实施药学服务的决议——迈向加强合理用药和以患者为中心的医疗服务的重要一步。
Healthcare (Basel). 2024 Jan 17;12(2):232. doi: 10.3390/healthcare12020232.
7
Pharmacovigilance teaching and learning: a mixed cross-sectional analysis of the Portuguese public higher education system.药物警戒教学与学习:对葡萄牙公立高等教育系统的混合横断面分析。
BMC Med Educ. 2024 Jan 3;24(1):13. doi: 10.1186/s12909-023-04963-1.
8
Public-private partnership (3Ps) in ensuring safe use of medicines: An Indian experience.公私合作伙伴关系(3Ps)在确保药品安全使用方面的作用:印度的经验。
Front Public Health. 2022 Aug 11;10:930696. doi: 10.3389/fpubh.2022.930696. eCollection 2022.
9
Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions.药物不良反应、多种合并症和多种药物治疗:对 1 个月医疗入院的前瞻性分析。
BMJ Open. 2022 Jul 4;12(7):e055551. doi: 10.1136/bmjopen-2021-055551.
10
Drug-related deaths among inpatients: a meta-analysis.住院患者与药物相关的死亡:一项荟萃分析。
Eur J Clin Pharmacol. 2022 Feb;78(2):267-278. doi: 10.1007/s00228-021-03214-w. Epub 2021 Oct 18.
Impact of antimicrobial stewardship interventions on Clostridium difficile infection and clinical outcomes: segmented regression analyses.
抗菌药物管理干预对艰难梭菌感染和临床结局的影响:分段回归分析。
J Antimicrob Chemother. 2018 Feb 1;73(2):517-526. doi: 10.1093/jac/dkx413.
4
Adverse drug reactions in high-risk pregnant women: A prospective study.高危孕妇的药物不良反应:一项前瞻性研究。
Saudi Pharm J. 2017 Nov;25(7):1073-1077. doi: 10.1016/j.jsps.2017.01.005. Epub 2017 Feb 2.
5
Drug-related deaths in hospital inpatients: A retrospective cohort study.住院患者的药物相关死亡:一项回顾性队列研究。
Br J Clin Pharmacol. 2018 Mar;84(3):542-552. doi: 10.1111/bcp.13471. Epub 2018 Jan 11.
6
Chemotherapy-induced neutropenia and the prognosis of colorectal cancer: a meta-analysis of cohort studies.化疗引起的中性粒细胞减少与结直肠癌的预后:队列研究的荟萃分析
Expert Rev Anticancer Ther. 2017 Nov;17(11):1077-1085. doi: 10.1080/14737140.2017.1380521. Epub 2017 Sep 25.
7
The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis.住院患者中药物相关不良事件的患病率——一项系统评价和荟萃分析
Eur J Clin Pharmacol. 2017 Dec;73(12):1539-1549. doi: 10.1007/s00228-017-2330-3. Epub 2017 Sep 5.
8
Risk factors for adverse drug reactions in pediatric inpatients: A cohort study.儿科住院患者药物不良反应的危险因素:一项队列研究。
PLoS One. 2017 Aug 1;12(8):e0182327. doi: 10.1371/journal.pone.0182327. eCollection 2017.
9
Surgical prophylaxis with gentamicin and acute kidney injury: a systematic review and meta-analysis.庆大霉素用于外科预防与急性肾损伤:一项系统评价和荟萃分析
Ann Transl Med. 2017 Mar;5(5):100. doi: 10.21037/atm.2017.03.06.
10
Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis.老年人因药物不良反应导致的住院情况:一项荟萃分析。
Eur J Clin Pharmacol. 2017 Jun;73(6):759-770. doi: 10.1007/s00228-017-2225-3. Epub 2017 Mar 1.